Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications
HyMedPoly aims to develop new therapies based on biomedical drug-free antibacterial polymers and inorganic materials for drug-free antibacterial hybrid biopolymers for infections.
Infection has become one of the toughest problems in the medical world, and as bacteria become more resistant to drugs there are fewer effective antibiotics to fight against pathogens.
The ultimate goal is to develop a new generation of professionals who will play a pivotal role in pushing forward this challenging and knowledge-intensive field for the coming decades to benefit the European economy and will be able to bring state-of-the-art technology to industry, advance products for hospitals and personal healthcare and develop new and improved therapeutic strategies.
HyMedPoly is a four year project and has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 643050.
Lucideon is the project coordinator and has co-supervised seven of the Early Stage researchers; five with the University of Erlangen-Nuremberg and two with the University of Southampton.
Senior Scientist, Dr. Mark Cresswell and Principal Consultant and Head of Medical Materials, Prof. & Dr. Xiang Zhang presented at the 'Drug-free Antibacterial Technology for Medical Applications' Event in Cambridge.
Two documents from HyMedPoly are available for download on the right hand side of your screen; An introduction to HyMedPoly and a booklet outlining potential applications resulting from the research.